Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Infectious Diseases Space Wide Open For Partnering Beyond Hep C, Conference Finds

This article was originally published in The Pink Sheet Daily

Executive Summary

The recent spotlight on hepatitis C doesn't mean that's the only hot area in infectious diseases for deals.

You may also be interested in...

Korea's CrystalGenomics Evaluates Phase II Options For Super Bug Antibiotic Candidate

SEOUL - South Korea's CrystalGenomics recently wrapped up the second-round of Phase I clinical trials for its antibiotic candidate CG400549 in Europe

Flu Vaccines, Increased Focus On Preventive Medicine Pique J&J's Interest In Crucell

If its $2.4 billion bid to buy Crucell N.V. succeeds, Johnson & Johnson will have managed to take a quick leap forward in the vaccines space, going overnight from a non-player to the number six company in the space, behind market leaders GlaxoSmithKline, Merck, Pfizer, Sanofi-Aventis and Novartis.

Hepatitis C Opportunities Light Up Infectious Disease Partnering Landscape

"Without question, hepatitis C is the number one exciting area in infectious diseases," insists Paul Zhang, a principal in the health care advisory group Easton Associates, LLC.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts